-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pancreatic cancer is the third most deadly cancer in the United States.
In a study published in the journal Oncotarget, Gregory Riggins, MD, professor of neurosurgery and oncology at Johns Hopkins University School of Medicine, his team used two different mouse models to determine anti-parasite resistance The drug mebendazole can slow down or prevent the growth and spread of early and late pancreatic cancer
Riggins said: "We think mebendazole has an effect at all stages
Riggins and his team injected mebendazole into mice that had been genetically modified to develop pancreatic cancer
Mebendazole was originally used to combat roundworm, hookworm and other parasitic infections by cutting off the parasite's nutrient supply.
Riggins said that he hopes to continue his team's research through human clinical trials
Riggins said: "We advocate the use of mebendazole as a treatment for pre-metastasis diagnosis to see if we can slow or prevent pancreatic cancer
references:
"Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer" by Tara Williamson, Michelle Carvalho de Abreu, Dimitri G.
